反応式
[CH:1]12[CH2:7][CH:4]([NH:5][CH2:6]1)[CH2:3][N:2]2[C:8]1[CH:9]=[N:10][C:11]([C:14]2[C:22]3[C:17](=[N:18][CH:19]=[CH:20][CH:21]=3)[N:16]([CH2:23][C:24]3[CH:29]=[CH:28][CH:27]=[CH:26][C:25]=3[F:30])[N:15]=2)=[N:12][CH:13]=1.C(=O)([O-])[O-].[Na+].[Na+].I[CH:38]([CH3:40])[CH3:39].O>CC(C)=O>[F:30][C:25]1[CH:26]=[CH:27][CH:28]=[CH:29][C:24]=1[CH2:23][N:16]1[C:17]2=[N:18][CH:19]=[CH:20][CH:21]=[C:22]2[C:14]([C:11]2[N:10]=[CH:9][C:8]([N:2]3[CH2:3][CH:4]4[CH2:7][CH:1]3[CH2:6][N:5]4[CH:38]([CH3:40])[CH3:39])=[CH:13][N:12]=2)=[N:15]1参加物
6
反応物 4
生成物 1
試薬・触媒・溶媒 1
実験手順
50 mg (0.13 mmol) of 3-[5-(2,5-diazabicyclo[2.2.1]hept-2-yl)-2-pyrimidinyl]-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine (example 9) are dissolved in 5 ml of absolute acetone, and 92 mg (0.87 mmol) of sodium carbonate are added. 64 mg (0.37 mmol) of 2-iodopropane are added to the suspension, and the mixture is stirred at RT overnight. The reaction solution is mixed with water and extracted with DCM. The organic phases are combined, washed with saturated aqueous sodium chloride solution, dried and filtered. The solvent is removed in vacuo, and the residue is purified by preparative HPLC with addition of small portions of aqueous hydrochloric acid. 25 mg (42% of theory) of the product are obtained.
後処理
- extractionextracted with DCM
- washwashed with saturated aqueous sodium chloride solution
- customdried
- filtrationfiltered
- customThe solvent is removed in vacuo
- customthe residue is purified by preparative HPLC with addition of small portions of aqueous hydrochloric acid
- custom25 mg (42% of theory) of the product are obtained
出典と根拠
- ORDレコード
- ord-3b9692a8f94a4325b9f1310600f39178
- 出典データセット
- uspto-grants-2006_08
- 特許番号
- US07091198B1
関連ノート
読み込み中…